February 19, 2019

What's this item about? What makes it interesting? Write a catchy description to grab your audience's attention...

March 19, 2018

Background Mazindol is under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD) because of its alertness-enhancing properties. A novel controlled-release (CR) formulation of mazindol was developed to allow once-daily dosing. Objective The aim of this study was to evaluate the effi- cacy of mazindol CR in adults with ADHD. Design We conducted a randomized, double-blind, placebo-controlled 6-week trial. Methods Subjects diagnosed with ADHD using the MiniInternational Neuropsychiatric Structured Interview (MINI) and with an ADHD Rating Scale, Diagnostic and Statistical Manual of Mental Disorders 5th Edition (ADHD-RS-DSM5) score C 28 were randomized to receive placebo or 1–3 mg/day of mazindol for 6 weeks. The primary endpoint was the reduction from baseline in the ADHD-RS-DSM5 score on Day 42. Secondary

Please reload

  • Facebook Social Icon